Preliminary LAG-3 Combo Data In Breast Cancer
Edison | Jun 23, 2017 07:08AM ET
Preliminary efficacy data, which Prima BioMed Ltd ADR (NASDAQ:PBMD) presented at ASCO from the 15-patient, safety run-in phase of its AIPAC study, showed sustained immune activation and an encouraging 47% tumour response rate in breast cancer following IMP321 plus paclitaxel combination therapy. Recruitment in the randomised Phase IIb component of AIPAC is ongoing, with top-line data likely by mid-2019. Efficacy data from the final two cohorts in the TACTI-mel trial of IMP321 plus Keytruda in melanoma are expected in H217 and H118 respectively. The 47% AIPAC response rate is in line with Phase I studies and consistent with our expectations, so we leave our valuation unchanged at A$252m (12c per share).
Encouraging response rate in AIPAC run-in
The 47% response rate in 15 metastatic breast cancer patients treated with IMP321 in combination with paclitaxel during the safety run-in study was similar to the 50% response rate reported in a previous Phase I trial, and higher than the c 30% response rate seen in published studies of weekly paclitaxel in breast cancer. Top-line PFS data from the ongoing 226-patient, randomised Phase IIb component of AIPAC could mature sometime between late 2018 and mid-2019; patients receive either 30mg of IMP321 or placebo, in combination with weekly paclitaxel. IMP321 is a LAG-3-based, antigen-presenting cell activator that enhances immune responses.
To read the entire report Please click on the pdf File Below:
Preliminary LAG-3 Combo Data In Breast Cancer
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.